Combination treatment for advanced melanoma that stopped responding to immunotherapy
Part of Cancer clinical trials.
This trial tests a new combination of drugs (axelopran and nivolumab) for people with advanced melanoma that stopped responding to earlier immunotherapy. The goal is to see if this combination can help your immune system fight the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma that cannot be removed by surgery or has spread to other parts of the body.
- You have already tried an immunotherapy drug called a PD-1 inhibitor (like nivolumab or pembrolizumab) and your cancer either didn't shrink or grew after treatment.
- You are 18 years or older and are able to take care of yourself (ECOG 0-2).
- Your daily opioid pain medication dose is 30 mg or less (morphine equivalent).
- You do not have active autoimmune disease, uncontrolled brain metastases, or a history of severe lung inflammation from prior treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower, less frequent dose of an immunotherapy drug called nivolumab for people with certain advanced cancers. The goal is to see if a reduced dose can still control cancer while causing fewer side effects.
This trial tests two drugs given before surgery to shrink melanoma that has spread to lymph nodes. The goal is to see if this combination helps remove the cancer more effectively.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests a new drug, OPM-101, combined with an immunotherapy drug (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy (bevacizumab) for people with advanced melanoma whose cancer continued to grow after previous immunotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new Unresectable Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.